Combined Abciximab REteplase Stent Study in Acute Myocardial Infarction (CARESS in AMI)

American Heart Journal

Volumn 148, Issue 3, 2004, Pages 378-385

  Di Mario, Carlo ^a   Bolognese, Leonardo ^b   Maillard, Luc ^c   Dudek, Dariusz ^d   Gambarati, Giampaolo ^e   Manari, Antonio ^f   Guiducci, Vincenzo ^f   Patrizi, Giampiero ^g   Rusconi, Luigi Cesare ^h   Piovaccari, Giancarlo ⁱ   Hibon, Agnes Ricard ^j   Belpomme, Vanessa ^j   Indolfi, Ciro ^k   Olivari, Zoran ^l   Steffenino, Giuseppe ^m   Zmudka, Krzysztof ⁿ   Airoldi, Flavio ^o   Panzarasa, Rita ^p   Flather, Marcus ^a   Steg, Philippe Gabriel ^q  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b IRCCS POLICLINICO SAN DONATO   (Italy)

^c Clinique Axium   (France)

^d JAGIELLONIAN UNIVERSITY   (Poland)

^e Pneumologia   (Italy)

^f S MARIA NUOVA HOSPITAL   (Italy)

^g Ospedale Civile   (Italy)

^h Ospedale G Ceccarini   (Italy)

ⁱ OSPEDALE DEGLI INFERMI   (Italy)

^j BEAUJON HOSPITAL   (France)

^k Magna Grecia University   (Italy)

^l OSPEDALE CA FONCELLO   (Italy)

^m S CROCE E CARLE HOSPITAL   (Italy)

ⁿ Krakowski Szpital Specjalistyczny Im Jana Pawła II   (Poland)

^o SAN RAFFAELE HOSPITAL   (Italy)

^p Mediolanum Cardio Research   (Italy)

^q BICHAT HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; RETEPLASE;

AGED; AMBULANCE; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; COST EFFECTIVENESS ANALYSIS; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART REINFARCTION; HOSPITAL; HOSPITAL ADMISSION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MORTALITY; MULTICENTER STUDY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION; STROKE; SYMPTOM; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANTIBODIES, MONOCLONAL; COST-BENEFIT ANALYSIS; DRUG THERAPY, COMBINATION; EMERGENCY MEDICAL SERVICES; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MYOCARDIAL INFARCTION; PLASMINOGEN ACTIVATORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RECURRENCE; STENTS; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 4644318789     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ahj.2004.03.038     Document Type: Article

References (32)

1. Keeley E.C., Boura J.A., Grines C.L. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction a quantitative review of 23 randomised trials. Lancet. 361:2003;13-20
2. Van den Werf F., Ardissino D., Betriu A., et al. Management of acute myocardial infarction in patients presenting with ST segment elevation. Eur Heart J. 24:2003;28-66
3. ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines) - executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to review the 1993 guidelines for percutaneous transluminal coronary angioplasty) endorsed by the Society of Cardiac Angiography and Interventions. Circulation 2001;103:3019-41
4. Henning R., Andersen M.D., Torstent T., et al. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med. 349:2003;733-742
5. Widimsky P., Budesinsky T., Vorac D., et al. Long distance transport for primary angioplasty vs immediate thrombolysis in acute myocardial infarction final results of the randomized national multicentre trial PRAGUE-2. Eur Heart J. 24:2003;94-104
6. Bonnefoy E., Lapostolle F., Steg G., et al. Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction a randomized study. Lancet. 360:2002;825-829
7. Dalby M., Bouzamondo A., Lechat P., et al. Transfer for primary angioplasty versus immediate thrombolysis in acute myocardial infarction a meta-analysis. Circulation. 108:2003;1809-1814
8. Widimsky P., Groch L., Zelizko M., et al. Multicentre randomized trial comparing transport to primary angioplasty vs immediate thrombolysis vs combined strategy for patients with acute myocardial infarction presenting to a community hospital without a catheterization laboratory. Eur Heart J. 21:2000;823-831
9. Ross A.M., Coyne K.S., Reiner J.S., et al. A randomized trial comparing primary angioplasty with a strategy of short acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction the PACT study. J Am Coll Cardiol. 34:1999;1954-1962
10. Montalescot G., Barragan P., Maillard L., et al. Platelet glycoprotein IIb/IIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med. 344:2001;1895-1903
11. Tcheng J.E., Kandzari D.E., Grines C.L., et al. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. Circulation. 108:2003;1316-1323
12. van't Hof AW, Ernst N, de Boer MJ, et al. Facilitation of primary coronary angioplasty by early start of a glycoprotein 2b/3a inhibitor: results of the ongoing tirofiban in myocardial infarction evaluation (On-TIME) trial. Eur Heart J 2004;25:837-46
13. Khot U.N., Neumann F.J., Brener S.J., et al. Is IIb/IIIa blockade state-of-the art for catheter based reperfusion? A meta-analysis of five randomized trials (EPIC, RAPPORT, ISAR-2, ADMIRAL, STOP-AMI) in acute myocardial infarction. J Am Coll Cardiol. 373:2001;68A
14. Collet J., Montalescot G., Lesty C., et al. A structural and dynamic investigation of the facilitating effect of glycoprotein IIb/IIIa inhibitors in dissolving platelet-rich clots. Circ Res. 90:2002;428-432
15. Herrman H.C., Moliterno D.J., Ohman E.M., et al. Trial of Abciximab with and without low-dose Reteplase for acute myocardial infarction. Circulation. 101:2000;2788-2794
16. Antman E.M., Giugliano R.P., Gibson C.M., et al. Abciximab facilitates the rate and extent of thrombolysis results of the thrombolysis in myocardial infarction (TIMI) 14 trial. Circulation. 99:1999;2720-2732
17. Brener S.J., Zeymer U., Adgey A.A., et al. Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction the integrilin and low-dose thrombolysis in acute myocardial infarction (INTRO AMI) trial. J Am Coll Cardiol. 39:2002;377-386
18. Topol E.J. GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition the GUSTO V randomized trial. Lancet. 357:2001;1905-1914
19. ASSENT-3 Investigators. Efficacy and safety of Tenecteplase in combination with noxaparin, Abciximab or unfractionated Heparin the ASSENT-3 randomized trial in acute myocardial infarction. Lancet. 358:2001;605-613
20. Savonitto S, Armstrong PW, Lincoff, et al. Risk of intracranial haemorrhage with combined fibrinolytic glycoprotein IIb/IIIa inhibitor therapy in acute myocardial infarction: dichotomous response as a function of age in the GUSTO V trial. Eur Heart J 2003;20:1807-14
21. Manari A., Guiducci V., Muia N., et al. Angioplasty in acute myocardial infarction after low dose alteplase and abciximab in transferred patients a comparison with primary angioplasty on site. Ital Heart J. 4:2003;311-317
22. Dudek D., Zmudka K., Kaluzag L., et al. Facilitated percutaneous coronary intervention in patients with acute myocardial infarction transferred from remote hospitals. Am J Cardiol. 91:2003;227-229
23. Maillard L., Hamon M., Khalife K., et al. A comparison of systematic stenting and conventional balloon angioplasty during primary percutaneous transluminal coronary angioplasty for acute infarction STENTIM-2 Investigators. J Am Coll Cardiol. 35:2000;1729-1736
24. Zahn R., Schiele R., Schneider S., et al. Primary angioplasty versus intravenous thrombolysis in acute myocardial infarction can we define subgroups of patients benefiting most from primary angioplasty? J Am Coll Cardiol. 37:2001;1827-1835
25. Juliard J.M., Feldman L.J., Steg P.J., et al. Relation of mortality of primary angioplasty to door-to-TIMI time. Am J Cardiol. 91:2003;1401-1405
26. De Luca G., Suryapranata H., Zijlstra F., et al. Symptom-onset-to-balloon time and mortality in patients with acute myocardial infarction treated by primary angioplasty. J Am Coll Cardiol. 42:2003;991-997
27. Cannon C.P., Gibson C.M., Lambren C.L., et al. Relationship of symptom-onset-to balloon time and door to balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. JAMA. 283:2000;2941-2947
28. Aversano T., Aversano L.T., Pasamani E., et al. Thrombolytic therapy vs primary percutaneous coronary intervention for myocardial infarction in patients presenting to hospitals without on-site cardiac surgery a randomized controlled trial. JAMA. 287:2002;1943-1951
29. Armstrong P.Q., Wagner G., Good S.G., et al. ST segment resolution in ASSENT 3 insights into the role of three difference treatment strategies for acute myocardial infarction. Eur Heart J. 24:2003;1515-1522
30. Antman E.M., Louwerenburg H.N., Baars H.F., et al. Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction. Circulation. 105:2002;1642-1656
31. Wallentin L., Goldstein P.W., Armstrong C.B., et al. Efficacy and safety of Tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting the assessment of the safety and efficacy of a new thrombolytic regimen. The ASSENT-3 PLUS randomized trial in acute myocardial infarction. Circulation. 108:2003;135-142
32. Kastrati A., Mehilli J., Schlotterbeck K., et al. Early administration of reteplase plus abciximab alone in patients with acute myocardial infarction referred for percutaneous coronary intervention. JAMA. 291:2004;947-954